Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver
disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is …

Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic
fatty liver disease (NAFLD) and is associated with disease progression, development of …

Nonalcoholic fatty liver (NAFL) and its sequelae are growing health problems. We performed
a genome-wide association study of NAFL, cirrhosis and hepatocellular carcinoma, and …

Background & Aims Although non-alcoholic fatty liver disease (NAFLD), non-alcoholic
steatohepatitis (NASH) and NASH with advanced fibrosis are closely associated with type 2 …

Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma …

Background & Aims Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver
disease (ALD) cannot reliably be distinguished by routine diagnostics, and the role of …

This update of evidence-based guidelines (GL) aims to translate current evidence and
expert opinion into recommendations for multidisciplinary teams responsible for the optimal …

OBJECTIVE Sodium–glucose cotransporter 2 (SGLT-2) inhibitors have been shown to
reduce liver fat in rodent models. Data regarding the effect of SGLT-2 inhibitors on human …

The correct identification of patients at increased risk of non-alcoholic steatohepatitis
(NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver …

OBJECTIVE To determine the effect of tirzepatide, a dual agonist of glucose-dependent
insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of …